Symbols / BFRG Stock $0.77 -4.72% Bullfrog AI Holdings, Inc.

Healthcare • Health Information Services • United States • NCM
BFRG (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Health Information Services
CEO Mr. Vininder Singh
Exch · Country NCM · United States
Market Cap 14.23M
Enterprise Value 8.07M
Income -6.50M
Sales 116.67K
FCF (ttm) -3.32M
Book/sh 0.19
Cash/sh 0.17
Employees 9
Insider 10d —
IPO Feb 13, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S 122.00
P/B 4.13
P/C —
EV/EBITDA -1.22
EV/Sales 69.19
Quick Ratio 3.25
Current Ratio 3.85
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.63
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-08-06
Earnings (prior) 2025-08-06
ROA -98.60%
ROE -183.04%
ROIC —
Gross Margin 18.76%
Oper. Margin -56.52%
Profit Margin 0.00%
Shs Outstand 18.45M
Shs Float 10.22M
Insider Own 19.71%
Instit Own 4.06%
Short Float 9.69%
Short Ratio 0.05
Short Interest 1.56M
52W High 2.04
vs 52W High -62.18%
52W Low 0.42
vs 52W Low 81.55%
Beta -2.29
Impl. Vol. —
Rel Volume 0.02
Avg Volume 11.61M
Volume 198.66K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.81
Price $0.77
Change -4.72%
About

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.77
Latest analyst target
3. DCF / Fair value
$-3.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.77
Low
—
High
—
Mean
—
News
RSS: Latest BFRG news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-22 HANSON JASON DAVID Director — 8,523 $0.00 $0
2025-08-22 ENRIGHT WILLIAM Director — 8,523 $0.00 $0
2025-08-22 ELSEY RAYMOND DONALD Director — 8,523 $0.00 $0
2025-08-22 BLACHER JOSHUA Chief Financial Officer — 15,000 $0.00 $0
2025-08-22 SINGH VININDER Chief Executive Officer — 75,000 $0.00 $0
2025-07-07 SINGH VININDER Chief Executive Officer — 29,002 $1.50 $43,625
2025-07-03 SINGH VININDER Chief Executive Officer — 20,998 $1.53 $32,911
2025-04-04 SINGH VININDER Chief Executive Officer — 5,895 $1.30 $7,686
2025-04-03 SINGH VININDER Chief Executive Officer — 44,105 $1.44 $66,408
2024-10-09 SINGH VININDER Chief Executive Officer — 5,695 $2.59 $14,727
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.12
0.00
-100.00%
0.07
+550.00%
0.01
Operating Revenue
0.12
0.00
-100.00%
0.07
+550.00%
0.01
Cost Of Revenue
0.09
0.00
-100.00%
0.01
+550.00%
0.00
Reconciled Cost Of Revenue
0.09
0.00
-100.00%
0.01
+550.00%
0.00
Gross Profit
0.02
0.00
-100.00%
0.06
+550.00%
0.01
Operating Expense
6.62
-8.57%
7.24
+33.33%
5.43
+120.18%
2.47
Research And Development
1.80
-19.05%
2.22
+55.19%
1.43
+135.14%
0.61
Selling General And Administration
4.82
-3.92%
5.01
+25.49%
3.99
+115.26%
1.86
General And Administrative Expense
4.82
-3.92%
5.01
+25.49%
3.99
+115.26%
1.86
Salaries And Wages
—
—
—
0.55
Other Gand A
4.82
-3.92%
5.01
+25.49%
3.99
+115.26%
1.86
Total Expenses
6.71
-7.26%
7.24
+33.20%
5.43
+120.31%
2.47
Operating Income
-6.59
+8.87%
-7.24
-34.82%
-5.37
-118.57%
-2.46
Total Operating Income As Reported
-6.59
+8.87%
-7.24
-34.82%
-5.37
-118.57%
-2.46
EBITDA
-6.49
+6.93%
-6.97
-32.20%
-5.28
-114.93%
-2.45
Normalized EBITDA
-6.49
+6.93%
-6.97
-32.20%
-5.28
-114.93%
-2.45
Reconciled Depreciation
0.00
+0.06%
0.00
-0.06%
0.00
+65.07%
0.00
EBIT
-6.49
+6.92%
-6.98
-32.19%
-5.28
-114.91%
-2.46
Total Unusual Items
—
—
-0.09
0.00
Total Unusual Items Excluding Goodwill
—
—
-0.09
0.00
Special Income Charges
—
—
-0.09
0.00
Other Special Charges
—
—
0.09
—
Net Income
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Pretax Income
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Net Non Operating Interest Income Expense
0.10
-60.22%
0.24
+132.03%
0.10
+130.18%
-0.35
Interest Expense Non Operating
0.01
-69.00%
0.02
-77.04%
0.08
-77.22%
0.35
Net Interest Income
0.10
-60.22%
0.24
+132.03%
0.10
+130.18%
-0.35
Interest Expense
0.01
-69.00%
0.02
-77.04%
0.08
-77.22%
0.35
Interest Income Non Operating
0.10
-60.83%
0.26
+42.02%
0.18
+39922.44%
0.00
Interest Income
0.10
-60.83%
0.26
+42.02%
0.18
+39922.44%
0.00
Other Income Expense
—
—
-0.09
-20352.51%
0.00
Other Non Operating Income Expenses
—
—
-0.09
-20352.51%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Net Income From Continuing Operation Net Minority Interest
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Net Income From Continuing And Discontinued Operation
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Net Income Continuous Operations
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Normalized Income
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Net Income Common Stockholders
-6.50
+7.68%
-7.04
-31.42%
-5.36
-91.11%
-2.80
Diluted EPS
—
-0.85
+4.49%
-0.89
-80.12%
-0.49
Basic EPS
—
-0.85
+4.49%
-0.89
-80.12%
-0.49
Basic Average Shares
—
8.25
+36.29%
6.05
+6.66%
5.67
Diluted Average Shares
—
8.25
+36.29%
6.05
+6.66%
5.67
Diluted NI Availto Com Stockholders
-6.50
+7.68%
-7.04
-31.42%
-5.36
-91.11%
-2.80
Preferred Stock Dividends
—
0.04
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2.81
-49.42%
5.55
+99.95%
2.78
+3354.80%
0.08
Current Assets
2.58
-53.42%
5.55
+100.23%
2.77
+3712.59%
0.07
Cash Cash Equivalents And Short Term Investments
2.18
-59.83%
5.44
+107.11%
2.62
+4451.29%
0.06
Cash And Cash Equivalents
2.18
-59.83%
5.44
+107.11%
2.62
+4451.29%
0.06
Cash Financial
—
—
—
0.06
Prepaid Assets
0.40
+258.84%
0.11
-23.50%
0.15
+872.55%
0.01
Total Non Current Assets
0.22
+5175.18%
0.00
-28.86%
0.01
-22.41%
0.01
Net PPE
0.00
-40.59%
0.00
-28.86%
0.01
-22.41%
0.01
Gross PPE
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Accumulated Depreciation
-0.01
-38.38%
-0.00
-62.24%
-0.00
-165.07%
-0.00
Other Properties
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Investments And Advances
0.12
0.00
—
—
Other Non Current Assets
0.10
—
—
—
Total Liabilities Net Minority Interest
0.67
+14.27%
0.59
+219.01%
0.18
-94.12%
3.14
Current Liabilities
0.67
+14.27%
0.59
+219.01%
0.18
-94.12%
3.14
Payables And Accrued Expenses
0.67
+14.27%
0.59
+219.01%
0.18
-87.93%
1.53
Payables
0.17
-61.43%
0.44
+320.56%
0.10
-80.95%
0.54
Accounts Payable
0.17
-61.43%
0.44
+320.56%
0.10
-80.95%
0.54
Current Accrued Expenses
0.50
+231.15%
0.15
+88.56%
0.08
-91.79%
0.98
Current Debt And Capital Lease Obligation
—
—
—
1.58
Current Debt
—
—
—
1.58
Other Current Borrowings
—
—
—
1.58
Current Deferred Liabilities
—
—
0.00
-100.00%
0.03
Current Deferred Revenue
—
—
0.00
-100.00%
0.03
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
2.14
-56.96%
4.96
+91.48%
2.59
+184.79%
-3.06
Common Stock Equity
2.14
-56.96%
4.96
+91.48%
2.59
+184.79%
-3.06
Capital Stock
0.00
+25.00%
0.00
+48.39%
0.00
+51.22%
0.00
Common Stock
0.00
+25.27%
0.00
+49.18%
0.00
+52.50%
0.00
Preferred Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
11.42
+25.29%
9.11
+49.53%
6.09
+7.45%
5.67
Ordinary Shares Number
11.42
+25.29%
9.11
+49.53%
6.09
+7.45%
5.67
Additional Paid In Capital
25.43
+16.87%
21.76
+76.21%
12.35
+820.28%
1.34
Retained Earnings
-23.29
-38.69%
-16.79
-72.15%
-9.75
-121.75%
-4.40
Total Equity Gross Minority Interest
2.14
-56.96%
4.96
+91.48%
2.59
+184.79%
-3.06
Total Capitalization
2.14
-56.96%
4.96
+91.48%
2.59
+184.79%
-3.06
Working Capital
1.91
-61.44%
4.96
+91.76%
2.59
+184.38%
-3.07
Invested Capital
2.14
-56.96%
4.96
+91.48%
2.59
+275.32%
-1.48
Total Debt
—
—
—
1.58
Net Debt
—
—
—
1.52
Net Tangible Assets
2.14
-56.96%
4.96
+91.48%
2.59
+184.79%
-3.06
Tangible Book Value
2.14
-56.96%
4.96
+91.48%
2.59
+184.79%
-3.06
Available For Sale Securities
0.12
—
—
—
Current Notes Payable
—
—
—
0.00
Investmentin Financial Assets
0.12
0.00
—
—
Preferred Stock Equity
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.52
+1.57%
-5.61
+6.52%
-6.00
-558.84%
-0.91
Cash Flow From Continuing Operating Activities
-5.52
+1.57%
-5.61
+6.52%
-6.00
-558.84%
-0.91
Net Income From Continuing Operations
-6.50
+7.09%
-6.99
-30.58%
-5.36
-91.11%
-2.80
Depreciation Amortization Depletion
0.00
+0.06%
0.00
-0.06%
0.00
+65.07%
0.00
Depreciation
0.00
+0.06%
0.00
-0.06%
0.00
+65.07%
0.00
Depreciation And Amortization
0.00
+0.06%
0.00
-0.06%
0.00
+65.07%
0.00
Other Non Cash Items
-0.12
—
0.16
-60.59%
0.41
Stock Based Compensation
1.01
+7.10%
0.94
+49.42%
0.63
+85.66%
0.34
Operating Gains Losses
—
—
—
—
Change In Working Capital
0.08
-81.71%
0.44
+130.38%
-1.44
-226.80%
1.14
Change In Prepaid Assets
0.01
-67.38%
0.03
+126.20%
-0.13
-772.55%
-0.01
Change In Payables And Accrued Expense
0.07
-82.93%
0.40
+131.57%
-1.28
-213.17%
1.13
Change In Accrued Expense
0.34
+371.18%
0.07
+108.52%
-0.84
-228.10%
0.65
Change In Payable
-0.27
-180.59%
0.33
+175.46%
-0.44
-192.62%
0.48
Change In Account Payable
-0.27
-180.59%
0.33
+175.46%
-0.44
-192.62%
0.48
Change In Other Working Capital
—
—
-0.03
-245.45%
0.02
Investing Cash Flow
0.00
0.00
0.00
+100.00%
-0.01
Cash Flow From Continuing Investing Activities
—
0.00
0.00
+100.00%
-0.01
Net PPE Purchase And Sale
—
0.00
0.00
+100.00%
-0.01
Purchase Of PPE
—
0.00
0.00
+100.00%
-0.01
Capital Expenditure
—
—
—
-0.01
Financing Cash Flow
2.37
-71.80%
8.42
-1.71%
8.57
+785.81%
0.97
Cash Flow From Continuing Financing Activities
2.37
-71.80%
8.42
-1.71%
8.57
+785.81%
0.97
Net Issuance Payments Of Debt
0.00
0.00
+100.00%
-0.22
-122.74%
0.97
Issuance Of Debt
0.18
-67.65%
0.56
-29.55%
0.80
-21.52%
1.02
Repayment Of Debt
-0.18
+67.65%
-0.56
+44.78%
-1.02
-1976.50%
-0.05
Long Term Debt Issuance
—
0.00
-100.00%
0.10
0.00
Long Term Debt Payments
—
0.00
+100.00%
-0.32
0.00
Net Long Term Debt Issuance
—
0.00
+100.00%
-0.22
0.00
Short Term Debt Issuance
0.18
-67.65%
0.56
-19.45%
0.70
-31.36%
1.02
Short Term Debt Payments
-0.18
+67.65%
-0.56
+19.45%
-0.70
-1323.54%
-0.05
Net Short Term Debt Issuance
0.00
0.00
0.00
-100.00%
0.97
Net Common Stock Issuance
2.47
-70.33%
8.32
+14.01%
7.29
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.11
-92.92%
1.49
0.00
Net Other Financing Charges
-0.09
—
—
—
Changes In Cash
-3.15
-211.95%
2.81
+9.51%
2.57
+5286.65%
0.05
Beginning Cash Position
5.44
+107.11%
2.62
+4451.29%
0.06
+475.89%
0.01
End Cash Position
2.29
-57.90%
5.44
+107.11%
2.62
+4451.29%
0.06
Free Cash Flow
-5.52
+1.57%
-5.61
+6.52%
-6.00
-552.57%
-0.92
Interest Paid Supplemental Data
0.01
-69.00%
0.02
-80.67%
0.09
+1531.34%
0.01
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
2.47
-70.33%
8.32
+14.01%
7.29
0.00
Issuance Of Capital Stock
2.47
-70.33%
8.32
+14.01%
7.29
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category